Eton Pharmaceuticals' Engagement in Investor Conferences
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a pioneering organization in the pharmaceutical world, is dedicated to the development and commercialization of groundbreaking treatments for rare diseases. To further engage with investors and stakeholders, Eton is excited to announce that key members of its leadership team, including Sean Brynjelsen, the Chief Executive Officer, James Gruber, the Chief Financial Officer, and David Krempa, the Chief Business Officer, will attend two notable investor conferences in the coming weeks.
Details of the Investor Conferences
25th Annual B. Riley Securities Investor Conference
The first major event is the 25th Annual B. Riley Securities Investor Conference, where Eton's CEO, Sean Brynjelsen, will participate in a fireside chat scheduled for Thursday, May 22, at 11:15 AM ET, which will also be 8:15 AM PT for attendees in the Pacific Time zone. This year, the conference takes place at The Ritz-Carlton, Marina Del Rey, bringing together numerous investors from across the sector.
22nd Annual Craig-Hallum Institutional Investor Conference
Following that, Eton executives will also attend the 22nd Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28. This gathering will take place at the Depot Renaissance Hotel in Minneapolis, providing a fantastic platform for discussing the company's journey and future trajectory.
Setting up Meetings and Interaction
Eton encourages investors to schedule one-on-one meetings with the company during these conferences. To do this, representatives from B. Riley and Craig-Hallum are available to help facilitate these meetings. Interaction with potential investors is a significant aspect of Eton's growth strategy, and such opportunities are essential in showcasing the company’s promise.
About Eton Pharmaceuticals
Founded with the mission to specialize in rare diseases, Eton Pharmaceuticals is at the forefront of introducing innovative healthcare solutions. The organization boasts a portfolio of seven commercially available products designed for rare medical conditions. Among these offerings are notable treatments such as INCRELEX, ALKINDI SPRINKLE, GALZIN, and others. Moreover, Eton is advancing six additional product candidates in late-stage development, which include ET-400, ET-600, and the ZENEO hydrocortisone autoinjector, promising to boost its product line further.
As the demand for specialized treatments continues to grow, Eton Pharmaceuticals remains committed to research and development, nurturing new solutions to address unmet medical needs. Their efforts reflect a dedication not just to business growth, but to enhancing patient lives.
Investor Relations Contact Information
For those interested in further engagement or inquiries about our offerings, please reach out to our Investor Relations representative, Lisa M. Wilson at In-Site Communications, Inc. You can contact her via phone at 212-452-2793 or through email at lwilson@insitecony.com.
Frequently Asked Questions
What is the purpose of Eton Pharmaceuticals attending these conferences?
Eton Pharmaceuticals aims to engage with investors, showcase its product developments, and foster relationships that could enhance its investment opportunities.
How many products does Eton Pharmaceuticals currently have?
Eton currently offers seven commercial rare disease products and is developing six additional product candidates in late stages of development.
Where will the B. Riley Securities Investor Conference take place?
This conference will be held at The Ritz-Carlton, Marina Del Rey, providing an upscale setting for the event.
Are there opportunities for one-on-one meetings with Eton's executives?
Yes, attendees can schedule one-on-one meetings with Eton’s executives through their institutional sales representatives at B. Riley or Craig Hallum.
What is Eton Pharmaceuticals' main focus?
Eton Pharmaceuticals focuses on developing and commercializing therapeutic options for patients suffering from rare diseases, aiming to meet unmet medical needs.
